Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: Experimental studies in pigs

Acta Ophthalmologica Scandinavica

Volumn 83, Issue 2, 2005, Pages 184-190

  Laugesen, Caroline Schmidt ^a,c   Steffansen, Bente ^b,c   Scherfig, Erik ^a,c   la Cour, Morten ^c  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

5 Fluorouracil; Controlled release; Ocular drug delivery; Prodrugs; Proliferative vitreoretinopathy

Indexed keywords

ALKOXYCARBONYLFLUOROURACIL DERIVATIVE; FLUOROURACIL DERIVATIVE; PRODRUG; SILICONE OIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CILIARY DISK; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; DRUG SYNTHESIS; ENUCLEATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MATHEMATICAL MODEL; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SWINE; VITRECTOMY; VITREOUS BODY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BODY WATER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUOROURACIL; HALF-LIFE; MODELS, THEORETICAL; PRODRUGS; SILICONE OILS; SWINE; VITRECTOMY; VITREOUS BODY;

EID: 17644366821     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2005.00429.x     Document Type: Article

References (25)

1. Altan T, Temel A, Bavbek T & Kazokoglu H (1994): Hypotonic maculopathy after trabeculectomy with postoperative use of 5-fluorouracil. Ophthalmologica 208: 318-320.
2. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT & Aylward GW (2001): Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 108: 1179-1183.
3. Berger AS, Cheng CK, Pearson PA, Ashton P, Crooks PA, Cynkowski T, Cynkowska G & Jaffe GJ (1996): Intravitreal sustained release corticosteroid-5-fluorouracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 37: 2318-2325.
4. Blumenkranz MS, Hartzer MK & Hajek AS (1987): Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol 105: 396-399.
5. Blumenkranz M, Hernandez E, Ophir A & Norton EW (1984): 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91: 122-130.
6. Blumenkranz MS, Ophir A, Claflin AJ & Hajek A (1982): Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol 94: 458-467.
7. Bunt-Milam AH, Saari JC, Klock IB & Garwin GG (1985): Zonulae adherentes pore size in the external limiting membrane of the rabbit retina. Invest Ophthalmol Vis Sci 26: 1377-1380.
8. Buur A & Bundgaard H (1986): Prodrugs of 5-fluorouracil. V. 1-Alkoxycarbonyl derivatives as potential prodrug forms for improved rectal or oral delivery of 5-fluorouracil. J Pharm Sci 75: 522-527.
9. Campochiaro PA (2001): Pathogenesis of proliferative vitreoretinopathy. In: Ryan SJ, Wilkinson CP & Hengst TC (eds). Retina. St. Louis, Missouri: Mosby 2221-2227.
10. Fastenberg DM, Diddie KR, Delmage JM & Dorey K (1983): Intraocular injection of silicone oil for experimental proliferative vitreoretinopathy. Am J Ophthalmol 95: 663-667.
11. Fisher SA & Anderson DH (2001): Cellular effects of detachment of the neural retina and the retinal pigment epithelium. In: Ryan SJ, Wilkinson CP & Hengst TC (eds). Retina. St. Louis, Missouri: Mosby 1961-1986.
12. Jarus G, Blumenkranz M, Hernandez E & Sossi N (1985): Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 92: 91-96.
13. Kirchhof B & Sorgente N (1989): Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev Ophthalmol 16: 1-53.
14. Kirmani M, Santana M, Sorgente N, Wiedemann P & Ryan SJ (1983): Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 3: 269-272.
15. Leon JA, Britt JM, Hopp RH, Mills RP & Milam AH (1990): Effects of fluorouracil and fluorouridine on protein synthesis in rabbit retina. Invest Ophthalmol Vis Sci 31: 1709-1716.
16. Perkins SL, Gallemore RP, Yang CH, Guo H, Ashton P & Jaffe GJ (2000): Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. Retina 20: 514-519.
17. Peyman GA, Conway M, Khoobehi B & Soike K (1992): Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int Ophthalmol 16: 109-113.
18. Rubsamen PE, Davis PA, Hernandez E, O'Grady GE & Cousins SW (1994): Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 112: 407-413.
19. Silicone Study Group. (1992): Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol 110: 780-792.
20. Steffansen B (1993): Ocular Drug Delivery. Alkoxycarbonyl prodrugs of 5-fluorouracil dissolved or disperged in silicone oil 1000 as a novel controlled release system. Copenhagen: Bente Steffansen 1-109.
21. 1-alkoxycarbonyl prodrugs in silicone oil. Int J Pharm 132: 243-250.
22. Wiedemann P & Heimann K (1990): Toxicity of intraocular daunomycin. Lens Eye Toxic Res 7: 305-310.
23. Wiedemann P, Hilgers RD, Bauer P & Heimann K (1998): Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicentre clinical trial. Daunomycin Study Group. Am J Ophthalmol 126: 550-559.
24. WuDunn D, Cantor LB, Palanca-Capistrano AM et al. (2002): A prospective randomized trial comparing intraoperative 5-fluorouracil versus mitomycin C in primary trabeculectomy. Am J Ophthalmol 134: 521-528.
25. Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H & Jaffe GJ (1998): An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116: 69-77.